Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 446 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Inseparable Couples Dies 33 Hours Apart After 68 Years Of Marriage:... December 5, 2019 Job Loss During Cancer: How to Cope and Continue Treatment September 24, 2020 FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer May 10, 2018 A career forged in team science March 10, 2023 Load more HOT NEWS Vaping Pods Produce High Nicotine Levels in Young Users Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... Can Using Hair Dyes or Hair Relaxers Impact Your Cancer Risk? Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in...
